8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 15, 2008)

Filed April 15, 2008For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on April 15, 2008, to report its first-quarter financial results for the period ended March 30, 2008. The filing primarily includes a press release and supplementary financial data detailing the company's sales and earnings performance. Investors should note that this report provides an early look at JNJ's performance in early 2008, a period of significant economic uncertainty. The specific details within the press release and supplementary data would offer insights into key sales drivers and profitability trends across JNJ's diverse business segments, including pharmaceuticals, medical devices and diagnostics, and consumer health products. Analyzing these figures will be crucial for understanding the company's operational health and its ability to navigate the prevailing economic climate. The report's focus on sales and earnings sets the stage for a deeper dive into segment-specific performance and the underlying factors contributing to the reported results, aiding investors in their assessment of JNJ's financial trajectory.

Key Highlights

  • 1Johnson & Johnson reported its first-quarter 2008 financial results on April 15, 2008.
  • 2The 8-K filing includes a press release announcing sales and earnings for the quarter ended March 30, 2008.
  • 3The company provided unaudited comparative supplementary sales data and condensed consolidated statements of earnings.
  • 4This report offers an initial glimpse into JNJ's financial performance at the start of 2008.
  • 5Investors can analyze the provided data to understand trends in sales and earnings across JNJ's business segments.
  • 6The filing serves as an official disclosure of the company's quarterly financial condition and results of operations.

Frequently Asked Questions

This 8-K filing's primary purpose is to formally announce and provide the financial results, specifically sales and earnings, for Johnson & Johnson's first quarter ended March 30, 2008, as is standard practice for publicly traded companies.

The filing includes a press release detailing the first-quarter sales and earnings, as well as unaudited comparative supplementary sales data and condensed consolidated statements of earnings for the same period.

While this 8-K provides the overall sales and earnings, detailed segment-specific performance metrics would typically be found within the attached press release (Exhibit 99.15) and the supplementary sales data (Exhibit 99.20).

This 8-K filing is considered an update to provide timely information about the company's quarterly performance. More detailed financial statements and analyses, such as the full Form 10-Q, would be filed separately.